For the quarter ended June 2025, Qiagen (QGEN) reported revenue of $533.54 million, up 7.5% over the same period last year. EPS came in at $0.60, compared to $0.57 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $524.1 million, representing a surprise of +1.8%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.60.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales by Product Groups- Diagnostic solutions- NeuMoDx: $3 million versus $4.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -57.1% change.
- Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $34 million versus the four-analyst average estimate of $32.08 million. The reported number represents a year-over-year change of +41.7%.
- Sales by Product Groups- Diagnostic solutions- QuantiFERON: $129 million compared to the $127.14 million average estimate based on four analysts. The reported number represents a change of +12.2% year over year.
- Sales by Product Groups- Other: $22 million versus $16.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +57.1% change.
- Sales by Product Groups- PCR / Nucleic acid amplification: $80 million versus $80.33 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.
- Sales by Product Groups- Genomics / NGS: $59 million versus the three-analyst average estimate of $61.81 million. The reported number represents a year-over-year change of +1.7%.
- Sales by Product Groups- Diagnostic solutions: $206 million versus $200.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.4% change.
- Sales by Product Groups- Sample technologies: $166 million compared to the $164.15 million average estimate based on three analysts. The reported number represents a change of +1.2% year over year.
- Sales by Product Groups- Diagnostic solutions- Other: $40 million versus the two-analyst average estimate of $36.95 million. The reported number represents a year-over-year change of +2.6%.
View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned +5.7% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
